Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 20/20 | 0.84 |
| ▸ | NR4A2 | P43354 | 9/20 | 0.84 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.79 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.79 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.79 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4398584 | 0.93 | DHODH (0.75) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL502818 | 0.89 | DHODH (1.00) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| Vidofludimus SCHEMBL247888 | 0.89 | DHODH (1.00) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| Vidofludimus SCHEMBL29352865 | 0.89 | DHODH (1.00) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| Vidofludimus SCHEMBL28974266 | 0.88 | DHODH (0.98) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| Vidofludimus SCHEMBL18109121 | 0.87 | DHODH (0.89) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL31125352 | 0.87 | DHODH (1.00) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL502900 | 0.87 | DHODH (0.83) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| Vidofludimus SCHEMBL29869156 | 0.86 | DHODH (1.00) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL3919682 | 0.85 | DHODH (0.73) | DHODHNR4A2NR4A1JMJD7NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110251498-A | One kind adjusts active compound of Farnesoid X receptor and application thereof | 厦门大学 | 2019-09-20 | — | — | CN | claimed |
| WO-2018177151-A1 | COMPOUNDS MODULATING ACTIVITY OF FARNESOID X RECEPTOR AND METHODS FOR THE USE THEREOF | XIAMEN UNIVERSITY (CN) | 2018-10-04 | — | — | WO | claimed |
| US-8653138-B2 | Calcium salts of compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC MG (DE) | 2014-02-18 | — | — | US | claimed |
| EP-2966058-B1 | NOVEL CALCIUM SALTS OF COMPOUND AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2017-10-04 | — | — | EP | disclosed |
| EP-2966058-B1 | NOVEL CALCIUM SALTS OF COMPOUND AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2017-10-04 | — | — | EP | disclosed |
| EP-2966058-A1 | NOVEL CALCIUM SALTS OF COMPOUND AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2588446-B1 | NOVEL CALCIUM SALTS OF COMPOUND AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2015-09-09 | — | — | EP | disclosed |
| US-8653138-B2 | Calcium salts of compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC MG (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653138-B2 | Calcium salts of compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC MG (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653138-B2 | Calcium salts of compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC MG (DE) | 2014-02-18 | — | — | US | disclosed |
| EP-2588446-A1 | NOVEL CALCIUM SALTS OF COMPOUND AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2013-05-08 | — | — | EP | disclosed |
| US-7423057-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7423057-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7423057-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7176241-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-7176241-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-7176241-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20060199856-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4 SC AG (DE) | 2006-09-07 | — | — | US | disclosed |
| WO-2003006425-A9 | NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2004-02-26 | — | — | WO | disclosed |
| US-20030203951-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203951-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | DHODH, DLD, GCDH | DHODH 1/4885NR4A2 800/4885NR4A1 1271/4885 |
| US-20060199856-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | DHODH, DLD, HADHA | DHODH 1/4885NR4A2 587/4885NR4A1 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.